Barclays PLC Immuno Gen, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 15, 2024
BUY
$12.46 - $29.95 $3.73 Million - $8.97 Million
299,429 Added 87.37%
642,156 $19 Million
Q3 2023

Nov 07, 2023
BUY
$14.09 - $19.87 $1.07 Million - $1.51 Million
76,185 Added 28.58%
342,727 $5.44 Million
Q2 2023

Aug 03, 2023
SELL
$3.75 - $20.05 $2.19 Million - $11.7 Million
-584,193 Reduced 68.67%
266,542 $5.03 Million
Q1 2023

May 04, 2023
BUY
$3.67 - $4.92 $257,215 - $344,823
70,086 Added 8.98%
850,735 $3.27 Million
Q4 2022

Feb 13, 2023
BUY
$4.55 - $6.31 $765,091 - $1.06 Million
168,152 Added 27.45%
780,649 $3.87 Million
Q3 2022

Nov 03, 2022
BUY
$4.48 - $6.47 $2.67 Million - $3.85 Million
595,402 Added 3482.9%
612,497 $2.93 Million
Q2 2022

Aug 12, 2022
SELL
$3.15 - $5.76 $84,791 - $155,047
-26,918 Reduced 61.16%
17,095 $76,000
Q1 2022

May 16, 2022
SELL
$4.26 - $7.48 $1.94 Million - $3.4 Million
-454,311 Reduced 91.17%
44,013 $209,000
Q4 2021

Feb 14, 2022
BUY
$4.75 - $7.5 $1.39 Million - $2.19 Million
292,628 Added 142.26%
498,324 $3.7 Million
Q3 2021

Nov 09, 2021
BUY
$5.02 - $6.59 $161,458 - $211,954
32,163 Added 18.53%
205,696 $1.17 Million
Q2 2021

Aug 13, 2021
SELL
$5.79 - $8.6 $1.48 Million - $2.2 Million
-256,121 Reduced 59.61%
173,533 $1.14 Million
Q1 2021

May 13, 2021
BUY
$6.5 - $10.53 $1.55 Million - $2.51 Million
238,835 Added 125.16%
429,654 $3.48 Million
Q4 2020

Feb 11, 2021
SELL
$3.7 - $7.66 $60,657 - $125,578
-16,394 Reduced 7.91%
190,819 $1.23 Million
Q3 2020

Nov 12, 2020
SELL
$3.45 - $4.89 $354,477 - $502,432
-102,747 Reduced 33.15%
207,213 $746,000
Q2 2020

Aug 12, 2020
BUY
$3.32 - $5.34 $576,700 - $927,584
173,705 Added 127.49%
309,960 $1.43 Million
Q1 2020

May 13, 2020
SELL
$2.12 - $6.8 $321,665 - $1.03 Million
-151,729 Reduced 52.69%
136,255 $464,000
Q4 2019

Feb 10, 2020
BUY
$2.25 - $5.8 $79,060 - $203,800
35,138 Added 13.9%
287,984 $1.47 Million
Q3 2019

Nov 14, 2019
SELL
$2.22 - $3.39 $191,022 - $291,695
-86,046 Reduced 25.39%
252,846 $612,000
Q2 2019

Aug 14, 2019
BUY
$1.8 - $3.3 $404,841 - $742,209
224,912 Added 197.33%
338,892 $735,000
Q1 2019

May 15, 2019
BUY
$2.41 - $5.91 $124,018 - $304,128
51,460 Added 82.31%
113,980 $309,000
Q4 2018

Feb 14, 2019
SELL
$3.94 - $9.7 $53,792 - $132,434
-13,653 Reduced 17.92%
62,520 $300,000
Q3 2018

Nov 14, 2018
BUY
$8.6 - $11.26 $487,104 - $637,766
56,640 Added 289.97%
76,173 $722,000
Q2 2018

Aug 14, 2018
SELL
$9.52 - $12.15 $855,105 - $1.09 Million
-89,822 Reduced 82.14%
19,533 $190,000
Q1 2018

May 15, 2018
BUY
$6.7 - $12.95 $256,938 - $496,619
38,349 Added 54.01%
109,355 $1.15 Million
Q4 2017

Feb 14, 2018
SELL
$5.07 - $7.92 $158,685 - $247,888
-31,299 Reduced 30.59%
71,006 $455,000
Q3 2017

Nov 14, 2017
BUY
$5.4 - $8.47 $552,447 - $866,523
102,305
102,305 $784,000

Others Institutions Holding IMGN

# of Institutions
8
Shares Held
1.41M
Call Options Held
0
Put Options Held
0
View Full List

About ImmunoGen, Inc.

IMGN Quotes by TradingView
  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email